MEMPHIS, TN - May 18, 2009 - ACORN CRO, an oncology -focused CRO, has developed proprietary technology known as STAR (Site Tracking And Recruitment). The introduction of this dedicated technology tool will speed the site selection process as it automates the study feasibility process. "STAR was developed under the guidance of ACORN CRO's experienced project managers who sought to save valuable time during the study start-up phase. The resulting system delivers solutions that provide meaningful cost benefits to both sponsors and participating sites," remarked Edward J. Stepanski, PhD, COO.
STAR increases transparency and efficiency in the study feasibility/site selection process. The Site Repository contains all known information about each oncology research site, and enables rapid selection of potential study sites based upon sponsor/study requirements. It also reduces the need for sites to complete repetitive tasks and is estimated to save approximately 75% of the time sites traditionally spend on com pleting study feasibility forms. Through STAR, sponsors are able to v iew a report summarizing site identification metrics in real time. Sponsors will appreciate that STAR automatically sends reminder notifications throughout the process, allows complete tracking of the status of each site contacted, and reduces the time needed to definitively identify study sites.
"STAR is yet another way in which ACORN CRO leverages technology to provide added value and efficiency for its customers. STAR substantially speeds up the study start-up process which results in impressive economies of scale," added Kristie Lively, Vice President.
ACORN CRO will showcase STAR at the annual DIA meeting in San Diego, June 22-24, 2009 in booth #2039.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.